

---

DRAFT STATUTORY INSTRUMENTS

---

**2019 No.**

**The Human Medicines (Amendment  
etc.) (EU Exit) Regulations 2019**

**PART 10**

Amendment of Part 10 (exceptions to requirement for marketing authorisations etc)

**Amendment of regulation 168 (use of non-prescription medicines in the course of a business)**

**135.** In regulation 168, in paragraph (8)—

(a) in sub-paragraph (a), for “EEA State” substitute “approved country for import”; and

(b) for sub-paragraph (b) substitute—

“(b) imported from an approved country for import—

(i) it is manufactured or assembled in that country by a person who is the holder of an authorisation in that country in relation to its manufacture or assembly, and

(ii) it is imported by the holder of a wholesale dealer’s licence under Part 3 that includes the import of a medicinal product from such a country.”.

**Amendment of regulation 169 (mixing of general sale medicinal products)**

**136.** In regulation 169(9)(a), insert “UK” before “marketing authorisation”.

**Amendment of regulation 171 (exempt advanced therapy medicinal products)**

**137.** In paragraph regulation 171(2)(c) for “Regulation (EC) No 726/2004” substitute “regulation 49(1)”.

**Amendment of regulation 173 (exemption for certain radiopharmaceuticals)**

**138.** In regulation 173(c), insert “UK” before “marketing authorisation”.